{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:59:19Z","timestamp":1791266359314,"version":"4.1.0"},"reference-count":13,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,6,9]],"date-time":"2012-06-09T00:00:00Z","timestamp":1339200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Influenza Resp Viruses"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:p><jats:italic>Please cite this paper as:<\/jats:italic> Borders\u2010Hemphill and Mosholder (2012) U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic. Influenza and Other Respiratory Viruses 6(601), e129\u2013e133.<\/jats:p><jats:p><jats:bold>Background\u2002<\/jats:bold> The 2009 H1N1 influenza pandemic in the United States occurred from April 2009 to April 2010. The 2009 H1N1 influenza virus was susceptible to neuraminidase inhibitors (oseltamivir and zanamivir).<\/jats:p><jats:p><jats:bold>Objectives\u2002<\/jats:bold> To characterize the 2009 H1N1 influenza pandemic in the United States from April 2009 to April 2010 using weekly influenza antiviral prescription utilization data and the CDC\u2019s weekly reports of the number of visits for influenza\u2010like\u2010illnesses by the Influenza Sentinel Provider Surveillance Network.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> A proprietary outpatient data source used by the FDA, which captures adjudicated U.S. prescription claims for select influenza antiviral drugs, was used to conduct this analysis. Data were extracted weekly and analyzed for surveillance during the pandemic. Results were compiled at the end of the pandemic.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Oseltamivir has dominated the U.S. influenza antiviral market share of dispensed prescriptions since approval in October 1999 and was the primary influenza antiviral drug used during the 2009 H1N1 influenza pandemic. However, commercial availability of the suspension formulation of oseltamivir was reduced by high demand during the pandemic. Dispensed prescription trends of other influenza antiviral medications studied followed that those of oseltamivir, even antivirals for which the 2009 H1N1 strains showed resistance.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Weekly prescription utilization of all influenza antivirals used to treat influenza during the seasonal influenza outbreak followed the same trend of weekly reports of the number of visits for influenza\u2010like\u2010illnesses (ILI) by the Influenza Sentinel Provider Surveillance Network. The ILI epidemic curve resembled dispensed antiviral prescription trends (both overall and stratified by age), providing some corroboration for the surveillance data.<\/jats:p>","DOI":"10.1111\/j.1750-2659.2012.00384.x","type":"journal-article","created":{"date-parts":[[2012,6,9]],"date-time":"2012-06-09T06:25:17Z","timestamp":1339223117000},"source":"Crossref","is-referenced-by-count":9,"title":["U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic"],"prefix":"10.1111","volume":"6","author":[{"given":"Vicky","family":"Borders\u2010Hemphill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mosholder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,6,9]]},"reference":[{"key":"e_1_2_5_2_2","unstructured":"U.S. Department of Health & Human Services. Available athttp:\/\/www.hhs.gov\/secretary\/phe_swh1n1.html(Accessed 20 April 2010)."},{"key":"e_1_2_5_3_2","unstructured":"Centers for Disease Control and Prevention. Available athttp:\/\/www.cdc.gov\/h1n1flu\/estimates_2009_h1n1.htm(Accessed 26 October 2010)."},{"key":"e_1_2_5_4_2","unstructured":"Centers for Disease Control and Prevention. Available athttp:\/\/www.cdc.gov\/H1N1flu\/recommendations.htm(Accessed 19 April 2010)."},{"key":"e_1_2_5_5_2","unstructured":"IMS Health.IMS National Sales Perspectives\u2122 2009 Extracted 4\u20102010. File: 1004anti.dvr"},{"key":"e_1_2_5_6_2","unstructured":"Centers for Disease Control and Prevention. Available athttp:\/\/www.cdc.gov\/ncidod\/osr\/site\/sentinel\/surv\u2010sys.htm(Accessed 26 October 2010)."},{"key":"e_1_2_5_7_2","unstructured":"Centers for Disease Control and Prevention. Available athttp:\/\/www.cdc.gov\/h1n1flu\/65andolder.htm(Accessed 18 May 2010)."},{"key":"e_1_2_5_8_2","unstructured":"Roche Laboratories.Tamiflu supply letter. Available athttp:\/\/www.gene.com\/gene\/products\/information\/tamiflu\/pdf\/TAMIFLU_Supply_letter_09_04_2009.pdf(Accessed 12 May 2010)."},{"key":"e_1_2_5_9_2","unstructured":"FDA.Postmarket drug safety information for patients and providers. Available athttp:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm188236.htm(Accessed 14 May 2010)."},{"key":"e_1_2_5_10_2","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/003335491112600303","article-title":"Emergency department visits for antiviral adverse events during the 2009 H1N1 influenza pandemic","volume":"126","author":"Lovegrove MC","year":"2011","journal-title":"Public Health Rep"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028483"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2010.07.001"},{"key":"e_1_2_5_13_2","unstructured":"U.S. Census Bureau Population Division. Table 1.Annual estimates of the resident population for the United States regions states and Puerto Rico: April 1 2000 to July 1 2009(NST\u2010EST2009\u201001). Release Date: December 2009. Available athttp:\/\/www.census.gov\/popest\/data\/historical\/2000s\/vintage_2009\/index.html(Accessed 17 April 2012)."},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008945"}],"container-title":["Influenza and Other Respiratory Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1750-2659.2012.00384.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1750-2659.2012.00384.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T13:43:05Z","timestamp":1698673385000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1750-2659.2012.00384.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,9]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1111\/j.1750-2659.2012.00384.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1750-2659.2012.00384.x","archive":["Portico"],"relation":{},"ISSN":["1750-2640","1750-2659"],"issn-type":[{"value":"1750-2640","type":"print"},{"value":"1750-2659","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,9]]}}}